Breast Imaging

Imaging the Axilla in DCIS Without Microinvasion: An ACR-Guided Workflow

·
Imaging the Axilla in DCIS Without Microinvasion: An ACR-Guided Workflow

A 58-year-old woman presents for surgical consultation following a stereotactic biopsy that revealed ductal carcinoma in situ (DCIS), high-grade, without evidence of microinvasion. Her diagnostic mammogram and ultrasound of the breast showed no suspicious axillary lymph nodes, but a formal axillary evaluation is needed for preoperative staging before her planned lumpectomy. You need to decide on the most appropriate next imaging study to assess the axillary lymph nodes. This is a critical step that can significantly alter surgical planning.

This article provides a focused workflow for this specific clinical scenario: an adult with known DCIS without microinvasion who needs axillary evaluation. Based on the American College of Radiology (ACR) Appropriateness Criteria, the recommended initial imaging study is an axillary ultrasound, which is rated as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for an adult patient with a recent, biopsy-proven diagnosis of pure ductal carcinoma in situ (DCIS). The key inclusion criteria are:

  • The diagnosis is DCIS, confirmed on core needle biopsy.
  • There is no evidence of microinvasion or a frankly invasive component on the initial biopsy pathology.
  • The patient is being evaluated for definitive surgical treatment (e.g., lumpectomy or mastectomy).
  • A preoperative assessment of the axillary lymph nodes is clinically indicated to guide surgical management.

This workflow does not apply to patients in slightly different clinical situations, which have their own distinct imaging pathways. For example, this guidance is not intended for:

  • Patients with known invasive breast cancer: In these cases, axillary staging is standard, but the pre-test probability of nodal involvement is higher, and the overall staging algorithm is more complex.
  • Patients with DCIS with microinvasion (DCIS-MI): The presence of microinvasion increases the risk of nodal metastasis, potentially altering the rationale for imaging and subsequent management.
  • Patients opting for active surveillance: For select patients with low-risk DCIS who choose surveillance over immediate surgery, axillary evaluation may be deferred or follow a different protocol.

Correctly identifying the patient’s specific scenario is crucial for ordering the most appropriate and resource-conscious imaging study.

What Diagnoses Are You Working Up in This Scenario?

When ordering an axillary ultrasound for a patient with pure DCIS, the primary goal is to identify any signs of nodal metastasis, which would imply the presence of an unsampled focus of invasive cancer. While the risk is low, its discovery preoperatively is high-impact.

Occult Invasive Disease with Nodal Metastasis
This is the most consequential diagnosis you are investigating. Core needle biopsies only sample a small portion of the lesion. It is well-documented that a subset of cases diagnosed as pure DCIS on core biopsy are “upgraded” to invasive ductal carcinoma upon analysis of the entire surgical specimen. Finding a metastatic lymph node on preoperative ultrasound would be strong evidence of an underlying invasive component, prompting a change from a standard sentinel lymph node biopsy to a targeted axillary dissection or consideration of neoadjuvant therapy.

Benign Reactive Lymphadenopathy
This is a very common and expected finding. The breast biopsy procedure itself, or any underlying inflammation, can cause axillary lymph nodes to become enlarged and “reactive.” These nodes typically retain their normal benign morphologic features on ultrasound, such as a preserved fatty hilum and a thin, uniform cortex. Distinguishing these from malignant nodes is a primary task of the interpreting radiologist.

Intramammary Lymph Node
Occasionally, a lymph node located within the breast tissue itself can be mistaken for an axillary node. Ultrasound can clarify the node’s location and morphology. These are almost always benign but can harbor metastasis in rare cases.

Why Is Axillary Ultrasound the Recommended Study for This Presentation?

For a patient with known DCIS requiring axillary evaluation, the ACR designates axillary ultrasound as Usually Appropriate. This recommendation is based on the test’s excellent balance of diagnostic capability, safety, and accessibility for this specific clinical question.

The primary rationale for using ultrasound is its ability to assess lymph node morphology with high resolution. It can reliably identify nodes with suspicious features, such as a thickened cortex (>3 mm), a rounded shape (loss of the normal oval or reniform appearance), or complete effacement of the fatty hilum. The presence of such a node allows for a percutaneous, ultrasound-guided biopsy before surgery. This non-invasive approach provides crucial staging information that can prevent a second surgery if nodal disease is found intraoperatively or postoperatively.

Furthermore, axillary ultrasound is a safe and efficient choice. It involves no ionizing radiation (Relative Radiation Level: 0 mSv) and does not require intravenous contrast, avoiding potential allergic reactions or risks to renal function. It is widely available, relatively inexpensive, and can be performed quickly.

Alternative, more complex imaging studies are considered Usually not appropriate for this focused indication:

  • MRI of the breast without and with IV contrast: While valuable for assessing the extent of DCIS within the breast, MRI is less specific for evaluating axillary nodes and is a more resource-intensive examination. It is not the recommended primary tool for axillary staging in pure DCIS.
  • FDG-PET/CT of the whole body: This is a high-radiation modality (RRL: 10-30 mSv) designed for staging more advanced or metastatic cancers. Its use for preoperative axillary screening in pure DCIS, which has a very low incidence of nodal metastasis (typically <2-3%), represents a significant overuse of resources and is not indicated.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound will directly guide the next steps in the patient’s surgical and treatment planning. The workflow branches into three main paths.

If the ultrasound is positive (one or more suspicious nodes):
The definitive next step is an ultrasound-guided needle biopsy of the most abnormal-appearing lymph node. This is typically a fine-needle aspiration (FNA) or a core needle biopsy. If the biopsy confirms metastatic carcinoma, the patient’s stage is elevated, and surgical planning changes. The patient may proceed directly to an axillary lymph node dissection (ALND) in conjunction with their breast surgery, or they may be considered for neoadjuvant systemic therapy before any surgery.

If the ultrasound is negative (no suspicious nodes):
A negative preoperative ultrasound is reassuring but does not eliminate the need for surgical staging. The standard of care remains a sentinel lymph node biopsy (SLNB) at the time of the breast surgery. Ultrasound can miss microscopic metastases, and SLNB is the most sensitive method for detecting these small-volume deposits. The negative ultrasound simply helps confirm that SLNB is the appropriate initial surgical approach to the axilla.

If the ultrasound is indeterminate (equivocal findings):
In cases where a lymph node appears mildly abnormal but does not meet definitive criteria for malignancy (e.g., borderline cortical thickness), the decision to biopsy is based on clinical judgment and multidisciplinary discussion. Often, a biopsy is recommended to provide a definitive answer before surgery and avoid intraoperative uncertainty.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for DCIS requires careful attention to detail to avoid common missteps. For this specific scenario, be aware of the following pitfalls:

  • Skipping SLNB after a negative ultrasound: A negative axillary ultrasound is not a substitute for a surgical sentinel lymph node biopsy. It is a tool to identify patients with bulky nodal disease who may benefit from a preoperative biopsy and potentially avoid an SLNB altogether in favor of a full axillary dissection.
  • Misinterpreting post-biopsy reactive nodes: The recent breast biopsy can cause temporary, benign reactive changes in nearby axillary nodes. The radiologist must carefully evaluate nodal morphology to distinguish these changes from malignancy.
  • Assuming all DCIS is the same: High-grade or extensive DCIS has a higher rate of upgrade to invasive cancer and a slightly higher risk of nodal involvement. While the initial imaging choice (ultrasound) remains the same, the index of suspicion may be higher in these cases.

If an ultrasound-guided biopsy confirms axillary metastasis, the case should be escalated for discussion at a multidisciplinary tumor board to determine the optimal sequence of treatment, including potential neoadjuvant therapies.

Related ACR Topics and Tools

For a comprehensive overview of imaging recommendations across all clinical presentations of ductal carcinoma in situ, please refer to our parent topic guide. Additional tools can help you apply these criteria in your daily practice.

Frequently Asked Questions

Why not just go straight to sentinel lymph node biopsy (SLNB) without imaging?

Performing a preoperative axillary ultrasound can identify patients with positive lymph nodes before surgery. If a node is positive on an ultrasound-guided biopsy, the patient can proceed directly to an axillary lymph node dissection, potentially avoiding the need for a second surgery if the sentinel node returned positive after the initial operation.

What features make an axillary lymph node suspicious on ultrasound?

Suspicious features include a thickened cortex (generally greater than 3 mm), a rounded shape (loss of the normal oval ‘kidney bean’ shape), eccentric cortical thickening, and partial or complete replacement of the central fatty hilum by cortical tissue.

If the axillary ultrasound and subsequent biopsy are positive, does the patient still need an SLNB?

No. A biopsy-proven positive axillary node typically means the patient will proceed to a more extensive axillary lymph node dissection (ALND) or receive neoadjuvant therapy. The SLNB procedure is designed to find the *first* draining node when the nodes are not known to be involved; once metastasis is confirmed, the role of SLNB is superseded.

Is axillary ultrasound necessary for all DCIS cases?

Not necessarily. The decision is often based on institutional protocols and risk factors. For low-grade, small-volume DCIS, some surgeons may elect to proceed directly to lumpectomy and SLNB without preoperative imaging of the axilla. However, it is frequently performed for patients with high-grade or extensive DCIS, or for those planning a mastectomy, where identifying nodal disease preoperatively is particularly impactful.

Does the grade of DCIS (low, intermediate, high) affect the decision to order an axillary ultrasound?

Yes, it often does. High-grade DCIS has a higher likelihood of being associated with an occult invasive component compared to low-grade DCIS. Therefore, clinicians are more likely to order a preoperative axillary ultrasound for patients with high-grade or extensive DCIS, as the pre-test probability of finding a metastatic node, while still low, is higher than in low-grade disease.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026